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Background: The combination of genistein 27 mg, cholecalciferol 200 IU, citrated zinc 
  bisglycinate (4 mg elemental zinc) 20 mg per capsule in Fosteum, a prescription medical food 
regulated by the FDA and indicated for the dietary management of osteopenia and osteoporosis, 
was tested for drug interactions and to determine the pharmacokinetic profile for genistein, the 
principal bone-modulating ingredient in the product.
Methods: In vitro human liver microsome cytochrome P450 (CYP450) assays were used to test 
the product for potential drug interactions with the isoforms 1A2, 2C8, 2C9, 2C19, 2D6, and 3A4. 
Due to specific 2C8 and 2C9 inhibition, a steady-state pharmacokinetic study was performed to 
assess serum genistein concentrations by high-pressure liquid chromatography-coupled mass 
spectroscopy in healthy fasting (n = 10) and fed (n = 10) postmenopausal women.
Results: The product showed minimal inhibition of 1A2, 2C19, 2D6, and 3A4, exhibit-
ing IC50 . 10 µM, but 2C8 and 2C9 yielded IC50 of 2.5 µM and 2.8 µM, respectively, 
concentrations which are theroretically achievable when dosing the product twice daily. 
After seven days of administration in a steady-state pharmacokinetic study, significant 
differences were found for unconjugated genistein (including free and protein-bound), 
regarding time to peak concentration (1.88 ± 1.36 hours), maximum concentration reached 
(0.052 ± 0.055 µM), elimination half-life (2.3 ± 1.6 hours), and area under the concentration-
time curve (53.75 ± 17.59 ng . hour/mL) compared with results for total genistein (including 
glucuronidated and sulfonated conjugates) time to peak concentration (2.22 ± 1.09 hours), 
maximum concentration reached (2.95 ± 1.64 µM), elimination half-life (10.4 ± 4.1 hours), 
and area under the concentration-time curve (10424 ± 6290 ng . hour/mL) in fasting subjects. 
Coadministration of food tended to extend the time and extent of absorption as well as slow 
elimination of genistein, but not in a statistically significant manner.
Conclusion: Because the serum genistein concentrations achieved during pharmacokinetic 
testing at therapeutic doses were well below those required for enzyme inhibition in the in vitro 
liver microsome assays, these results indicate a low potential for drug interactions.
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Introduction
Renewed interest in botanically derived therapies has resulted in the recent marketing 
of products containing high concentrations of isoflavones for bone loss, both as food 
supplements and as prescription medical foods. Many epidemiological studies sup-
port an inverse relationship between isoflavone intake and bone loss and fracture rate. 
A large prospective study of 24,403 postmenopausal Chinese women, for example, International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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related soy protein and isoflavone consumption to   subsequent 
fracture incidence over a 4.5-year period.1 After age, body 
mass index, and lifestyle risk factors were controlled, a 
significant linear negative association was found for both 
soy protein and isoflavone consumption ($21 mg daily) 
and fracture risk.
Genistein is an isoflavone found in small quantities in 
certain legumes throughout the plant kingdom (Figure 1). 
Unfermented soybeans are a particularly rich source of 
genistin, the glucoside precursor of genistein, although the 
concentration varies with the strain, location, and envi-
ronmental conditions of cultivation of the plant. Another 
widely utilized source of genistin is Sophora japonica L.2 
Asian populations, for whom fermented soy food and other 
isoflavone containing plants are dietary staples, are estimated 
to consume 25–100 mg of isoflavone daily.3 The majority 
of isoflavone consumption is in the form of aglycone rather 
than as glucosides. In contrast, intake of isoflavones in the 
US is estimated at only 0.15–3 mg per day, with much of it 
being in glucoside forms.4,5 Therefore, non-Asian popula-
tions may not reap the benefits of high intake of isoflavone, 
in particular, genistein aglycone.
Mixed isoflavone studies demonstrate positive effects 
on bone markers and lipid profiles,6 vasomotor symptoms,7 
and mood8 in humans, as well as memory in an experimental 
animal model.9 In ovariectomized osteoporotic rats, Bitto et al 
showed that genistein restored better quality bone than 
alendronate, raloxifene, and estradiol as measured by bone 
mineral density, metabolic bone markers, fracture resistance, 
and bone histology.10 Additional studies showed that genistein 
prevented and restored bone in animal models of secondary 
osteoporosis induced by steroids.11,12 In well-controlled clini-
cal trials, purified genistein (54 mg/day) was shown to improve 
bone markers and increase bone mineral density over three 
years at a rate comparable with other standard therapies for 
osteoporosis.13–16 Other studies have demonstrated the ability 
of genistein to successfully manage vasomotor symptoms 
in postmenopausal women.17,18 Genistein, in experimental 
animal models, has anxiolytic and antidepressant effects.19–21 
Genistein has an excellent cardiovascular safety profile in well 
controlled clinical trials.22 Finally, genistein has a positive 
cancer risk profile in humans.15,23,24
Despite the widespread consumption of soya, soy   products, 
and their major isoflavones, little has been published regarding 
the metabolic fate of these molecules. Major metabolites are 
known to be glucuronides and sulfonates of isoflavones,25 but 
are poorly characterized, often because no reference standards 
are available26 and their influence on drug metabolic pathways 
is unknown. The extent to which genistein and its metabolites 
bind serum proteins in the body is not known, but is thought 
to be through an ionic interaction. Due to the introduction of 
purified and high-dose therapeutic genistein products onto the 
market, knowledge of the metabolism and pharmacokinetic 
profile of genistein is imperative if unanticipated interactions 
with other drugs are to be avoided.
A specially formulated medical food which contains 
genistein 27 mg, cholecalciferol 200 IU, and citrated zinc 
bisglycinate (4 mg elemental zinc) 20 mg per capsule 
(Fosteum) is taken twice daily under physician supervi-
sion for the clinical dietary management of osteopenia and 
osteoporosis.27 In this study, the interaction of genistein from 
the formulation was assessed by cytochrome P450 (CYP450) 
enzyme inhibition assays in human liver microsomes. In addi-
tion, a steady-state pharmacokinetic study was performed 
in healthy fasting and fed postmenopausal female subjects 
to determine if serum genistein levels become sufficiently 
high to make drug interactions a possibility. Results for 
both in vitro drug metabolic studies for the product and 
the pharmacokinetic profile in postmenopausal women are 
presented for genistein.
Methods
All chemicals, except where noted, were purchased from 
Sigma-Aldrich, St Louis, MO. To screen for the potential 
of genistein drug interactions, the formulation was initially 
diluted from a 10 mM dimethylsulfoxide stock standardized 
for genistein and incubated in duplicate at final concentra-
tions of 10 µM and 25 µM (genistein) with pooled probe 
substrates for CYP450 enzyme isoforms 1A2 (0.25 mg/mL), 
2C8 (0.05 mg/mL), 2C9 (0.025 mg/mL), 2C19 (0.5 mg/mL), 
and 2D6 (0.1 mg/mL) in a 200 µL well volume in 96-well 
plates (Nunc A/S, Roskilde, Denmark) containing human 
liver microsomes (from Xenotech LLC, Lenexa, KS) 
(MDS Pharma Services, King of Prussia, PA).28 Substrate 
  concentrations for each CYP450 isoform were set close to 
the Km (Table 1).
O HO
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Table 1 Standard probe substrates and metabolites (modified Greenford–Ware cocktail) for initial cytochrome P450 enzyme inhibition 
screens from the literature. Inhibitory activity using human liver microsomes found at 10 µM and 25 µM concentrations of genistein in 
Fosteum®. Ic50 values found for genistein in Fosteum for inhibition of cYP1A2, cYP2c8, cYP2c9, cYP2c19, and cYP2D6
CYP450  
isoform
Probe substrate Probe metabolite Liver microsome  
inhibition  
genistein (10 µM)
Liver microsome  
inhibition  
genistein (25 µM)
IC50† (µM)
Name Assay  
concentration  
(µM)
*Km (µM)
cYP1A2 Phenacetin 18.8 12.5 Paracetamol 20% 46% .50
cYP2c8 Paclitaxel 1 5 6α-hydroxypaclitaxel 53% 80% 2.5
cYP2c9 Tolbutamide 120 166 4-hydroxytolbutamide 59% 87% 2.8
cYP2c19 s-mephenytoin 100 40 4-hydroxymephenytoin 22% 56% 19
cYP2D6 Bufuralol 10 5 to 10 1-hydroxybufuralol 13% 34% .50
cYP3A4 Midazolam 5 10 1-hydroxymidazolam −1% 19% not  
tested
Notes: *Km = the substrate concentration at which the velocity of an enzyme-catalyzed reaction is half maximal; †Ic50 = half maximal inhibitory concentration.
Positive control inhibitors and the concentration at 
which each inhibited CYP450 isoforms to 100% were: 
furafylline (10 µM) for 1A2, montelukast (10 µM) for 2C8, 
sulfaphenazole (10 µM) for 2C9, benzylnirvanol (2 µM) 
for 2C19,29 quinidine (10 µM) for 2D6, and ketoconazole 
(1 µM) for 3A4. Each inhibitor was diluted from 10 mM 
dimethylsulfoxide stocks and assayed alongside the prod-
uct formulation containing genistein diluted from a 2 mM 
stock dissolved in dimethylsulfoxide. After incubation for 
30 minutes in a humidified incubator at 37°C, the reactions 
were terminated by adding 100 µL of acetonitrile. The assay 
utilized phosphate buffer (75 mM, pH 7.4) and the NADPH 
regenerating system (MgCl2, 3.3 mM; glucose-6-phosphate, 
3.3 mM; glucose-6-phosphate dehydrogenase, 1 U/mL; 
NADP+, 1.3 mM) which was added at the beginning of each 
reaction incubation.
Specific inhibition of CYP450 enzymes was measured 
in duplicate standardized to the 10 µM of genistein con-
tained in the formulation. The decrease in production of 
the specific probe metabolites (Table 1) was analyzed using 
liquid   chromatography-mass spectroscopy/mass spectros-
copy (LC-MS/MS, Applied Biosystems, Life Technologies 
Corp, Carlsbad, CA) along with selected reaction monitoring 
  transitions.30 The signal for each probe metabolite was integrated, 
and the metabolite to internal standard area ratio was generated. 
Percent inhibition was calculated by comparing the area ratios 
of the probe metabolite in the presence and absence of the test 
article. If genistein in the formulation inhibited an isoform 
to .50% at 10 µM, an analysis was then performed to establish 
an IC50 for each enzyme. CYP2C8 was also examined in IC50 
experiments due to its homology with the 2C9 isoform31 to 
assess its potential for drug interaction.
The formulation was diluted from a 2 mM stock stan-
dardized for genistein in dimethylsulfoxide and incubated in 
triplicate at eight final concentrations from 0.016 to 50 µM in 
half-log steps to determine an IC50 for the CYP450 isoforms 
A2, 2C8, 2C9, 2C19, and 2D6 using the same assay system 
described above. The signals for each probe metabolite were 
integrated and probe metabolite to internal standard peak area 
ratios were generated. Percent control was calculated by com-
paring the area ratios of the probe metabolite in the presence 
and absence of genistein using the following formula:
  % control = [(raw − min)/(max − min)] × 100
where raw = peak area ratios of test article, min = peak area 
ratios of estimated lower limits of detection and max = peak 
area ratios of solvent control. IC50 s were fitted to the percent 
control data using XLFit (version 2.0 build 39, ID-BS Ltd). 
Although in vitro in nature and not tissue-specific, this analy-
sis helps determine whether a human pharmacokinetic study 
is needed to assess the serum concentration and potential 
drug interactions with a medical food.
The pharmacokinetic study was conducted according 
to the guidelines of the Declaration of Helsinki, and all 
procedures involving human subjects were approved by the 
Institutional Review Board (Quorum IRB, Seattle, WA). 
Written informed consent was obtained from all subjects. 
Subjects were free to withdraw from the study at any time, 
for any reason. Twenty women (aged 50–66, mean 57), at 
least one year postmenopausal and in good general health 
were enrolled into the trial. To avoid dietary contamination 
of the study results, subjects were excluded if they had used 
supplements containing phytoestrogen/isoflavone for 60 days 
or consumed products containing soy or isoflavone for at least 
two weeks prior to the screening visit. Due to preliminary 
results suggesting the possibility of CYP2C8 or 2C9 inhibi-
tion by genistein, use of 2C8/2C9 substrates, ie, warfarin, International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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amitryptyline, fluoxetine, diclofenac, ibuprofen, naproxen, 
celecoxib, phenytoin, losartan, irbesartan, glipizide, gly-
buride, and tolbutamide were proscribed for 60 days prior 
to screening and throughout the study period. No subject 
discontinued participation in the trial.
This was an open-label, multidose, steady-state pharma-
cokinetic study. Originally 26 subjects were screened with 
a physical examination and fasting hematology, chemistry 
safety laboratory panels, and by interview 1–2 weeks prior 
to the baseline visit. At the baseline visit, 20 subjects were 
randomized to take one capsule of the medical food formula-
tion twice daily either with food (breakfast and supper) or on 
an empty stomach (one hour prior to breakfast and supper). 
The first dose was taken on the evening of the baseline visit. 
All subjects were instructed to report eight days later to begin 
pharmacokinetic sampling.
On the morning of the eighth day, subjects reported to 
the clinical research site, and trough serum samples were 
obtained, following which subjects took the study product 
either on an empty stomach (fasting) or with a light breakfast 
(fed). Subjects under the fasting condition consumed the 
breakfast after the one-hour sample draw. Blood samples 
(about 8 mL per sample) were obtained by venipuncture into 
vacutainer tubes and allowed to clot at room temperature. 
Serum samples were taken at hours 1, 2, 4, 6, 8, 10, 12, 24, 
36, 48, 72, and 96 after dosing. Samples were then centrifuged 
for 15 minutes at 1500 rpm and the serum was aliquoted into 
cryovials and stored at −70°C. Subjects left the clinical site 
following the 12-hour sampling interval and returned for the 
24-, 36-, 48-, 72- and 96-hour blood draws. The study was 
constructed to record any and all adverse events. All samples 
remained frozen until analysis by liquid chromatography and 
mass spectroscopy.
Isolation and high-performance liquid chromatogra-
phy analysis was done according to Thomas et al, with 
  modifications.32 To determine unconjugated genistein 
(defined as free plus protein-bound), aliquots of 0.05 mL for 
each time point, as well as blank plasma obtained prior to 
consumption of the formulation and a deuterated genistein 
(genistein-d4) internal standard (0.1 mL of 50 ng/mL in 20% 
methanol in distilled water, Cambridge Isotopes Laboratories, 
Andover, MA) were added together to individual polypropyl-
ene culture tubes for extraction of unconjugated genistein. 
Then 0.2 mL of 0.25 M sodium acetate, pH 5.0, was added 
to each sample. The determination of total genistein (defined 
as the sum of unconjugated, glucuronidated, and sulfonated 
genistein) was performed by the addition of 0.1 mL of 
900 U/mL β-glucuronidase and sulfatase in sodium acetate 
buffer   followed by a 1.5-hour incubation at 40°C. Both 
unconjugated and total genistein samples were vortexed for 
one minute, then 2.5 mL of 1:1:1 hexane to methyl tert-butyl 
ether to methylene chloride extraction solvent was added to 
each tube. The samples were then vortexed gently for 15 min-
utes followed by a 10-minute centrifugation at 3000 rpm to 
separate the aqueous and organic layers. The aqueous layer 
of each sample and controls were then frozen at −80ºC, and 
the organic layer poured into 10 mL conical glass screw-cap 
tubes where they were dried with nitrogen gas at 40°C.
The dried extracts were reconstituted with 0.2 mL of 
1:1 mobile phase buffer A (0.05% formic acid and 5 mM 
ammonium formate in distilled water) to mobile phase   buffer 
B (0.05% formic acid and 5 mM ammonium formate in an 
80:10:10 ratio, acetonitrile to methanol to distilled water). 
Samples were vigorously vortexed for five minutes and 
then centrifuged for two minutes at 1500 rpm to remove 
any insoluble material. The supernatants were removed and 
transferred to 0.25 mL polypropylene injection vials with 
caps for each chromatography run.
A standard curve using .98.5% pure genistein   (Primus 
Pharmaceuticals Inc, Scottsdale, AZ) in a 1:1 mixture 
of mobile phase buffer A to mobile phase buffer B was 
established by injecting 20 µL samples of 0.25 ng/mL 
to 10,000 ng/mL in two-fold increases. A 20 µL volume 
was first injected onto the loading column (MetaChem 
  SafetyGuard ODS 10 × 4.6 mm, Agilent Technologies, Santa 
Clara, CA) and then onto the analytical C18 50 × 4.6 mm 
5 µm column (Waters Atlantis, Waters Corp, Milford, MA). 
The LC program for the loading column was: injection of 
the sample followed by a one-minute isocratic wash with 
20% buffer B, then a linear gradient in 0.5 minutes to 80% 
buffer B, followed by an isocratic wash with 80% buffer B 
and, finally, a wash step of 100% buffer B. The LC program 
after the sample traversed the loading column and then trav-
eled through a switch valve (VICI Valco Instruments Co Inc, 
Houston, TX) onto the analytical column was: a one-minute 
isocratic wash with 50% buffer B, a linear gradient from 
50%–80% buffer B in 0.5 minutes, followed by an isocratic 
wash with 80% buffer B. Genistein standards show a reten-
tion time of 2.78 minutes on the analytical column.
LC/MS/MS was used to determine the plasma concentra-
tion of genistein so that a comparison could be done with the 
IC50 values established for CYP2C8 and 2C9. The analysis 
of extracted samples was performed using a Sciex API4000 
QTrap MS/MS (AB SCIEX Research and Development, 
Concord, ON, Canada) equipped with an ESP(+) interface, 
and was used with an ion source temperature of 450°C. For International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
143
genistein combination in postmenopausal women
MS/MS measurements, a collision energy of 30 eV was used 
for the (M + H)+ transitions used to monitor unlabeled and 
genistein-d4 (m/z 271.0→215.1 and 275.1→219.1, respec-
tively) with a dwell time of 0.15 seconds and a sampling 
cone-skimmer potential of 50 V . Isotope dilution for analysis 
of genistein and characterization of the genistein-d4 was done 
according to Holder et al for comparison with the samples 
obtained from both fasting and fed subjects.33
Total genistein concentrations were obtained at each 
time point in duplicate for each subject and pharmacoki-
netic   analysis performed. The primary variables of interest 
were Cmax (the maximum observed concentration of total 
genistein), Tmax (the elapsed time at which Cmax was observed), 
T1/2 (the elapsed time at which genistein concentration was 
half of Cmax), and the imputed area under the curve (AUC) 
estimating the total body exposure to genistein over time. 
The AUC was computed by interpolating the concentrations 
of total genistein in the intervals between recordings using 
trapezoid calculations. Imputation was performed by cubic 
spline estimation. Each of these variables was computed for 
each participant, and mean values and standard deviations 
were computed for the sample. Any value exhibiting a .3 
standard deviations (n = 3) from the mean was removed 
from the analysis. A Student’s t-test was conducted for 
each measure to see if the observed difference in means was 
significant. Descriptive statistics were presented for each of 
the primary outcome variables.
Results
Data from a preliminary in vitro screen of CYP450 inhibi-
tory activity using human liver microsomes at 10 µM and 
25 µM concentrations of genistein from the formulation 
are shown in Table 1. Genistein from the medical food for-
mulation inhibited CYP2C8 and CYP2C9 metabolism of 
6α-hydroxypaclitaxel and 4-hydroxytolbutamide by 53% 
and 59%, respectively, at a 10 µM concentration, which 
suggests a significant inhibitory effect on both isozymes. 
Although below the cutoff threshold, genistein also displayed 
moderate (.20%) inhibition of CYP1A2 and CYP2C19, thus 
replicating the inhibition of CYP1A2 reported by Hu et al.34 
Genistein showed a mild 13% inhibition of CYP2D6 at 10 
µM. Based on these data, an additional concentration-ranging 
experiment was conducted to determine IC50 values for 
CYP1A2, CYP2C9, CYP2C8, CYP2C19, and CYP2D6.
Figures 2A–E shows the inhibition titration curves for 
CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 
to establish IC50 values. Table 1 also shows a summary of 
these IC50 titration values found in human liver microsomes. 
Genistein did not inhibit CYP1A2, CYP2C19, or CYP2D6 at 
concentrations that would suggest a drug interaction potential 
by this analysis (IC50s . 50, 19, and .50 µM, respectively, 
Table 1). The CYP3A4 isoform was not tested by IC50 analysis 
due to a low initial inhibition in vitro. These data raise the 
possibility that the genistein-containing formulation might 
inhibit the metabolism of CYP2C8 (IC50 = 2.5 µM) and 
CYP2C9 (IC50 = 2.8 µM) to a clinically significant degree. 
A human pharmacokinetic study was performed to evaluate 
this potential further.
To validate the LC methodology, serum was extracted and 
run under standard conditions. The added internal standard, ie, 
genistein-d4, was found among background peaks in serum 
not exposed to the formulation. Unconjugated genistein from 
subjects produced a distinct peak which aligned with the 
control genistein-d4 run in serum and with the deuterated 
standard run without exposure to serum (data not shown). 
The calibration peak of .98.5% for pure genistein used for 
determination of genistein concentration in each sample also 
corresponded directly to those concentrations determined by 
spiking serum with genistein-d4. Mass spectroscopy analysis 
of the serum containing unconjugated genistein showed the 
concentration to be low (30–500-fold less) compared with 
the total genistein which contained glucuronidated and sul-
fonated forms in either fasting or fed subjects. Descriptive 
statistics summarizing the 96-hour pharmacokinetic data 
are presented for both unconjugated (Table 2A) and total 
genistein (Table 2B).
For unconjugated genistein among all fasting subjects, 
an average Cmax of 14.1 ± 14.8 ng/mL (0.0528 ± 0.077 µM) 
was reached at an average of 1.88 hours following the 
final dose of genistein, whereas the average Cmax for fed 
subjects, 3.01 ± 1.50 ng/mL (0.011 ± 0.006 µM), was 
reached at an average of 2.1 hours, suggesting that the food 
matrix decreased and delayed the absorption of genistein 
(Table 2A). There was no way to determine unconjugated 
genistein levels from serum after about 24 hours, no matter 
the fed state, due to limits of detection using the LC/MS 
method. Although the average mean Cmax for unconjugated 
genistein was lower among individuals who took the medical 
food formulation with food compared with fasting subjects, 
this difference was not statistically significant (P = 0.21). 
This may be a spurious result, however, due to inaccura-
cies in detection at low levels of genistein. Two subjects 
were removed from the unconjugated genistein analysis 
of the fasting pharmacokinetic data group and one subject 
from total genistein analysis of the fed group due to more 
than three standard deviation differences in Tmax values. In International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Figure 2 genistein aglycone inhibition titration curves for cYP1A2 (A), CYP2C8 (B), CYP2C9 (C), CYP2C19 (D), and CYP2D6 (E).International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
145
genistein combination in postmenopausal women
Table 2 Free compared with total genistein aglycone from the medical food formulation under fasting and fed prandial states in 
postmenopausal women
A. Unconjugated genistein
Subjects n Unconjugated genistein Mean ± SD
Fasting 8* cmax (ng/mL, µM) 14.1 ± 14.8, 0.052 ± 0.055
Tmax (hours) 1.88 ± 1.36
T1/2 (hours) 2.3 ± 1.6
AUc (ng . hr/mL) 53.75 ± 17.59
Age (yrs) 56.8 ± 3.9
Fed 10 cmax (ng/mL, µM) 3.01 ± 1.50, 0.011 ± 0.006
Tmax (hours) 2.10 ± 1.10
T1/2 (hours) 3.4 ± 2.1
AUc (ng . hr/mL) 11.3 ± 7.62
Age (yrs) 56.5 ± 5.7
B. Total genistein
Subjects n Total genistein Mean ± SD
Fasting 9* cmax (ng/mL, µM) 798.0 ± 441.9, 2.95 ± 1.64
Tmax (hours) 2.22 ± 1.09
T1/2 (hours) 10.4 ± 4.1
AUc (ng . hr/mL) 10424 ± 6290
Age (yrs) 56.8 ± 3.9
Fed 10 cmax (ng/mL, µM) 701.6 ± 310.7, 2.60 ± 1.15
Tmax (hours) 3.10 ± 1.73
T1/2 (hours) 11.8 ± 3.7
AUc (ng . hr/mL) 9775 ± 6157
Age (yrs) 56.5 ± 5.7
Note: *Two subjects were removed from the unconjugated genistein analysis of the fasting PK data group and one subject from total genistein analysis of the fed group due 
to .3 standard deviation differences in Tmax values.
fasting subjects, total genistein reached an average Cmax of 
798.0 ± 441.9 ng/mL (2.95 ± 1.64 µM) at an average of 
2.22 hours following the final dose of genistein, whereas 
the average Cmax for fed subjects was 701.6 ± 310.7 ng/mL 
(2.60 ± 1.15 µM), reached at an average of 3.1 hours after the 
final dose, again suggesting that the food matrix delayed the 
time course of absorption (Table 2B). The difference in Cmax 
of total genistein between fasting and fed subjects was only 
about 14%. This difference was not statistically significant 
(P = 0.148). The T1/2 of unconjugated genistein for the fasting 
group was approximately 2.3 hours compared with 3.4 hours 
for the fed group, suggesting a delay in absorption due to the 
food matrix (Table 2A). These half-lives were much shorter 
compared with those found for total genistein, ie, 10.4 hours 
and 11.8 hours, respectively, for fasting and fed groups. This 
may be due to second-pass metabolism of the conjugated 
forms of genistein (Table 2B). Determination of an accurate 
AUC for unconjugated genistein was difficult due to low 
detection levels after 24 hours, so approximate AUCs are 
shown in Table 2A. Area under the curve of total genistein 
for the fasting group was 10423.7 ± 6290.0 ng . hr/mL and 
9775.1 ± 6157.4 ng . hr/mL for the fed group, showing no 
significant difference (P = 0.79, Table 2B). The pharma-
cokinetic profile for both fasting and fed subjects is shown 
in Figure 3AB.
The overall serum clearance of unconjugated genistein 
was very similar in both fasting and fed subjects, although 
the fasting group had a more rapid and greater uptake fol-
lowed by a biphasic excretion (Figure 3A). Total genistein 
serum clearance, which includes both unconjugated genistein 
and its metabolites, shows initial equal uptake, but the fed 
group levels off before exhibiting a similar excretion profile 
(Figure 3B). This may also represent interference from the 
food matrix. No adverse events were reported during the 
study in either the fasting or fed group.
Discussion
The health benefits of isoflavones are directly related to their 
bioavailability. Bioavailability, in general, is dependent upon 
an individual’s state of health, bacterial flora in the gut, gender, 
age, the food matrix in which the compounds are consumed, 
the mix of isoflavones in the products, and host genetics.35 
Genistein is freely absorbed from the intestine, and a large 
fraction is converted to the 7β-O-glucuronide as it crosses International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Figure 3 Pharmacokinetic profile of unconjugated A) and total B) genistein from the medical food in fasting and fed prandial states.
the brush border and ultimately enters the portal vein,36 a 
process that is influenced by intestinal bacteria.37,38 Recent 
ex vivo data using isolated human gastrointestinal tract tissue 
suggest that genistein may also undergo sulfonation in the 
small intestine, although the extent to which these sulfonates 
are absorbed following dietary intake is unknown.39 The exact 
percentages of glucuronidated and sulfonated metabolites 
after crossing the lumen are also unknown, although it is clear 
that only a small percentage of the parent molecule remains 
as unconjugated genistein once it reaches the liver. In the International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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liver, genistein undergoes additional biotransformation via 
CYP450-mediated hydroxylation,34 followed by glucuroni-
dation and sulfonation by UDP-glucuronosyltransferase and 
sulfotransferases, respectively.36 Genistein 7β-O-glucuronide 
can be recovered from bile after infusion of genistein into the 
small bowel of rats.40 As much as 70% of the genistein recov-
ered from bile is in the form of glucuronidated conjugates, 
with smaller amounts reappearing in the distal duodenum 
and jejunum.36 The vast majority of circulating genistein in 
serum has been found to be in the form of glucuronidated 
and sulfonated conjugates, which represent excretion forms 
of the molecule.37 Little is known about the bioactivity of 
conjugated isoflavones. This represents an area of research 
that should be explored in the future.
In vitro screening for drug metabolism is an initial and 
common pharmaceutical industry practice, and required to 
assure safety of new prescription therapeutics.41 The use of 
one sample concentration (10 µM) at the apparent Km of the 
substrate provides a preliminary assessment of the Ki, as 
described by the Cheng-Prusoff equation.42 At the apparent 
Km of the substrate, the IC50 value is equal to or double the 
value of the Ki, for a noncompetitive or competitive inhibitor, 
respectively. Because most clinically important drug inhibi-
tors have Kis , 10 µM, it is recommended that a sample 
showing inhibition of $50% be further characterized by 
determination of an IC50 or a Ki.
Genistein has not been shown to activate CYP450 metab-
olizing enzymes,43 although various inhibitory interactions 
with human CYP450 enzymes have been noted. Genistein 
has been found to inhibit minor CYP450 enzymes, such as 
CYP2A6 (34), CYP1A1*2, −1E and −2A1,44 and CYP1A1.45 
Two concentrations, 10 µM and 25 µM, standardized to 
genistein in the medical food formulation were used in this 
current analysis. A 25 µM genistein concentration was also 
included in the analysis because previously published data 
showed moderate CYP450 inhibition for the 1A2 and 2C19 
isoforms.34 The genistein in the formulation was tested for 
inhibition of six major drug metabolizing CYP450 enzymes 
as per industry standard drug interaction protocols, rather 
than focusing on the minor isozymes.46 No interactions of 
genistein with CYP2D6 were known, but this isozyme was 
also tested due to the large number of medications with 
which it interacts.
Genistein did not inhibit CYP2D6 to the extent that it 
would present a drug interaction potential. Hu et al found 
that genistein inhibited the CYP1A2 isozyme in vitro, with 
an IC50 of 16 µM.34 In our study, genistein inhibited CYP1A2 
moderately (20%) in a comparable human liver microsome 
system at 10 µM, but, in contrast with the results of Hu et al, 
exhibited an IC50 . 50 µM (Table 1). Our results are more 
similar to those reported by Roberts-Kirchoff et al, who also 
found moderate inhibition of CYP1A2.45 Unlike data reported 
on inhibition of CYP3A4,45,47 genistein showed no inhibition 
at a 10 µM concentration (Table 1). Differences in CYP3A4 
results may be due to the different probe substrates used in 
the analyses. Genistein showed only moderate inhibition of 
CYP2C19 (22%), but did not present the possibility for a drug 
interaction with an IC50 value of 19 µM (Table 1). Tolleson 
et al showed that CYP2C9 catalyzed genistein conversion.48 
In our study, genistein inhibited CYP2C8 and CYP2C9 at a 
sufficient level (53% and 59%, respectively) to potentially 
cause drug interaction (Table 1). CYP2C8 and 2C9, with 
extensive gene sequence homology,31 showed similar inhi-
bition, with genistein having IC50 s of 2.5 µM and 2.8 µM, 
respectively. CYP2C8 and 2C9 detoxify major drug classes, 
such as nonsteroidal anti-inflammatory drugs, antiepileptic 
and antidiabetic agents, statins, angiotensin II receptor 
antagonists, diuretics, and warfarin. Given the possibility that 
serum genistein levels at 54 mg per day could reach similar 
concentrations as the IC50 s for these two CYP450 isozymes, 
a pharmacokinetic study in postmenopausal women was 
initiated to determine the serum concentration achievable 
with the recommended therapeutic dose.
Results from isoflavone pharmacokinetic studies have 
been shown to vary with gender, concomitant food intake, 
and individual idiosyncrasy.49–51 Several single bolus 
mixed aglycone isoflavone studies have been performed 
from a food or supplement matrix. Setchell et al found 
that administering a single bolus of genistein at 50 mg 
(n = 6) gave a Tmax for total genistein of 5.2 hours, a Cmax of 
341 ± 74 ng/mL (1.26 ± 0.27 µM), T1/2 of 6.78 ± 0.84 hours, 
and AUC of 4540 ± 1410 ng . h/mL, as determined by gas 
chromatography and mass spectroscopy analysis.52 Uncon-
jugated genistein was very low and reached a peak at about 
12.6 ng/mL ( approximately 0.047 µM). Similar results were 
obtained by Bloedon et al.53 The Tmax, Cmax, and AUC values 
from our study were probably greater than those found in 
previous studies due to the steady-state dosing regimen used 
in our protocol. Administration of approximately 35 mg of 
mixed genistein/daidzein over two and four weeks (n = 8) 
produced steady-state concentrations of 2 µM and 1.7 µM, 
respectively.54 Unconjugated genistein was not determined 
in this steady-state administration protocol. The total 
steady-state concentration is somewhat lower than what 
was observed in our study, but the difference may be due 
to the administration of a mixture of isoflavones rather than International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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pure genistein and the lower daily dose. Similar to what 
was observed in the present study, large standard deviations 
for Tmax and Cmax were found, suggesting the variability of 
bacterial flora in the gut or differences in enzyme content 
and/or in luminal cells in individual subjects, which can 
modify genistein.
Ullman et al reported in a 14-day steady-state 
pharmacokinetic  study  using  60  mg  of  synthetic 
genistein (.98.5%, n = 10) a total genistein Cmax of 
929.2 ± 327.1 ng/mL (approximately 3.4 µM).55 The 
AUC was 13544.8 ± 7222.3 ng . hr/mL. Tmax and T1/2 were 
6.0 ± 4.0 and 9.7 ± 6.9 hours. The observed Tmax, Cmax, and 
AUC for the Ullman study,55 using synthetic genistein of 
similar purity, was similar to our findings, but T1/2 values 
were more than double what we observed for total genistein. 
Differences in isoflavone absorption and secretion have 
been noted between men and women.51 There was a higher 
proportion of males (n = 8) to females (n = 2) in the Ull-
man et al study.55 This is in contrast with our study, which 
was performed in postmenopausal women. A head-to-
head study in equivalent populations is needed for proper 
comparison of naturally derived genistein and synthetic 
genistein to answer this question. Another study, in which 
30 mg of synthetic genistein (98.5%) was given daily for 
seven days to 12 subjects, showed a total genistein Cmax 
of approximately 500 ng/mL, with a steady-state AUC of 
about 5940 ng . hr/mL, a Tmax of 5.3 hours, and a T1/2 of 
about 8.2 hours for the conjugated and about four hours 
for unconjugated genistein.56 More than likely, the Cmax and 
AUC are reduced compared with the Ullman et al study of 
the same product,55 based on half the dose (30 mg versus 
60 mg) being administered.56 Differences in Tmax and T1/2 
may be different due to the study containing all females56 
compared with the Ullman et al study.55
Although the maximal amount of circulating total 
genistein found in our pharmacokinetic study is close 
to the IC50 values for CYP2C8 and 2C9 determined by 
in vitro studies, over 95% of circulating genistein exists in 
conjugated forms which are excreted.37 The extent to which 
genistein metabolites inhibit various CYP450 isozymes is 
currently unknown, and purified standards are not currently 
available for this analysis. Little is known about the tissue 
distribution of unconjugated and conjugated forms to assess 
tissue-specific interactions.
Using a mouse uterine cytosolic estrogen competi-
tive binding analysis, Zhang et al found that genistein 
had a 48-fold higher affinity for estrogen receptors than 
its glucuronides.57 Normally, tissue studies are performed 
if the serum concentration is high enough to cause a drug 
interaction to determine tissue-specific accumulation or 
effects. However, in this case, the unconjugated level of 
genistein did not reach a level to necessitate tissue   studies. 
Further work is needed on the conjugated forms of genistein 
to determine if they truly have the potential for drug 
  interactions. Finally, major drug interactions in populations 
which consume high levels of aglycone isoflavones from 
fermented foods do not exist.
Deficiencies in this study include the inability to guar-
antee absolutely the absence of all isoflavone-containing 
oral intake and the lack of suitable analyses for genistein 
conjugates, the availability of which would have allowed for 
a slightly more comprehensive evaluation of total potential 
genistein bioavailability.
Conclusion
Although this medical food formulation shows a potential 
for drug interactions in vitro, a steady-state pharmacokinetic 
study demonstrates that the serum concentration of genistein 
attained by daily dosing of 54 mg in postmenopausal women 
does not reach a level which poses a hazard. The intake of 
food with the formulation, although not statistically sig-
nificant, does seem to affect the uptake of genistein mini-
mally. Therefore, care must be taken not to consume large 
amounts of nutrients which compete for intestinal receptors 
binding genistein, in order to assure proper uptake and 
bioavailability.
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